I et 52- ugers dobbeltblindet kontrolleret forsøg reducerede vildagliptin (50 mg to gange daglig) baseline- HbA1c med - 1% sammenlignet med - 1, 6% for metformin (titreret til 2 g/ dag) blev statistisk non- inferioritet ikke opnået.
In a 52-week double-blind controlled trial, vildagliptin (50 mg twice daily) reduced baseline HbA1c by -1% compared to -1.6% for metformin (titrated to 2 g/ day) statistical non-inferiority was not achieved.